Previous close | 93.45 |
Open | 93.45 |
Bid | 84.30 |
Ask | 90.55 |
Strike | 195.00 |
Expiry date | 2024-06-21 |
Day's range | 93.45 - 93.45 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Moderna (MRNA) is advancing three of its vaccines into Phase Three trials as the pharmaceutical giant hopes to expand its product pipeline past its COVID-19 vaccine, sales of which fell by 43% year-over-year in 2023. Yahoo Finance Health Reporter Anjalee Khemlani recaps her interview with Moderna CEO Stéphane Bancel, who discussed the company's $1 billion investment into mRNA manufacturing sites in China. "There's a very strong agreement at the highest level between the US government and China government that they want to collaborate on health care, on the climate, and on food insecurity," Bancel says. "We have all those vaccine in respiratory and in latent. We want as many people in the world to be able to benefit from those products so that we prevent disease." For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Luke Carberry Mogan.
Moderna stock rose after the company said its next-generation Covid shot beat out the original. Is MRNA stock a buy or a sell right now?
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.